Correction to: An international survey of allogeneic hematopoietic cell transplantation for X-linked agammaglobulinemia

Correction to: Journal of Clinical Immunology (2023) 43:1827–1839

https://doi.org/10.1007/s10875-023-01551-2

Table 1 carried an erratum. The reference numbers were incorrect.

Table 1.

Patient characteristics and transplant procedure in XLA patients

Patient	Age (At the diagnosis)	Variant of BTK (gene, protein)	Age (At HCT)	Indication	Neurological complication	IBD	Infectious complication at HCT	CLD	Donor source	HLA matching (genotype)	Donor	Conditioning regimen (dose, days)	MAC, RTC, or RIC	GVHD prophylaxis	NCC 108/kg	CD34 106/kg	Reference
1	3	NA	5	Bacterial infection	None	None	Infection of the right lower limb, Chronic nasosinusitis	None	BM	10/10	Sibling	BU 12 mg/kg, CY 6.0 g/m2, CD3 McAb 6 mg/kg	MAC	CsA, sMTX	4.6	NA	[9]
2	5	A to G variant (AAAGGGGAACTA to AAAGGGAGCTG) at position − 29 in the BTK promoter	14	AML	None	None	None	None	PBSC	10/10	Unrelated donor	TBI 12 Gy, CY 120 mg/kg, ETP 40 mg/kg	MAC	Tac, sMTX	-	10.4	[10]
3	NA	NA	28	Bacterial infection	Meningitis	None	None	None	PBSC	6/6	Sibling	Flu 180 mg/m2, CY 100 mg/kg, TBI 3 Gy, ATG (T) 2.5 mg/kg	RIC	CsA, MMF	6.7	4.8	[13
4	2	c.1908 + 1G > C	24	ALL (MRD+)	None	None	None	+*	PBSC	6/6	Sibling	TBI 13.2 Gy, ETP (Data of dose is none)	MAC	CsA, sMTX	-	5.0	[17
5	0.7	NA	1.4	Bacterial infection	None	None	Pneumonia, Gastroenteritis	None	BM	6/6	Sibling	TT 8 mg/kg, Treo 28 g/m2, Flu 160 mg/m2	RT-MAC	Tac, sMTX	-	7.0	[16, 18]
6	1	Exon 3 to 5 deletion	1.7	Bacterial infection	None	None	Pneumonia	None	BM	6/6	Sibling	BU 12.8 mg/kg, Flu 160 mg/m2	RIC	Tac, sMTX	-	NA	[16, 18]
6-re			2						PBSC	6/6	Sibling	TT 8 mg/kg, Treo 28 g/m2, Flu 160 mg/m2	RT-MAC	Tac, sMTX	-	6.5	[16, 18]
7	1.5	c.777–3 C > G	9	Bacterial infection	Meningoencephalitis	None	Pneumonia, Diarrhea, Otitis media	None	PBSC	5/10	NA	Treo, Flu (Data of dose is NA)	RIC	PTCY, Tac	-	5.5	-
8	1	NA	6	Bacterial infection	None	None	Pneumonia, Gastroenteritis	None	PBSC	6/6	Sibling	TT, Treo, Flu (Data of dose is NA)	RT-MAC	Tac, sMTX	-	6.8	-
9	3	c.1815_1819delinsTCACTGAACACATTGCCCAAG, p.E605Dfs*3	4	Bacterial infection	None	None	+*	None	PBSC	9/10	Unrelated donor	BU 12 mg/kg, Flu 150 mg/m2, Ara-C 3 g/m2, CY 50 mg/kg, ATG (T) 6 mg/kg	RIC	PTCY, CsA, sMTX	25.5	8.9	[15]
10	23	c.1902G > C, p.W634C	24	Lymphoma	None	+	+*	+*	PBSC	5/10	Haploidentical related donor	BU 12.8 mg/kg, Flu 200 mg/m2, CY 50 mg/kg, ATG (T) 10 mg/kg	RIC	PTCY, CsA, sMTX	16.4	7.4	[15]
11	0.7	c.1750 + 2T > C	8	Norovirus infection	None	None	Norovirus enteropathy	None	PBSC	12/12	Unrelated donor	TT 10 mg/kg, Treo 42 g/m2, Flu 150 mg/m2, ALZ 0.5 mg/kg	RT-MAC	CsA, MMF	11.7	9.0	[8]
12	0.1	IVS10 -5 T > G	11	SCD	None	None	None	None	BM	10/10	Father	BU AUC 63 mg*h/ml, TT 10 mg/kg, Flu 150 mg/m2, ATG (G) 45 mg/kg	RT-MAC	CsA, MMF	2.9	2.4	-
13	0.7	с.763 C > T, p.R255*	10	Crohn’s disease	None	+	None	None	PBSC	9/10	NA	Treo 42 g/m2, Flu 150 mg/m2, ATG (T) 5 mg/kg, RTX 100 mg/m2	RIC	TCRαβ depletion, Tac, sMTX	6.7	7.1	[14]
14	3	c82C > T, p.R28C	14	Aichi virus infection	None	None	Aichi virus infections (Liver and kidney failure, Obstructive pancreatitis)	None	PBSC	10/10	Sibling	Treo 42 g/m2, Flu 150 mg/m2	RIC	CsA, MMF	-	5.0	[11]
15	0.5	NA	14	Bacterial infection	NA	NA	NA	NA	UCB	5/6	Unrelated donor	BU 12 mg/kg, CY 200 mg/kg, CD3 McAb 50 mg	MAC	CsA, sMTX, MMF	0.42	3.5	[12]
16	2	BTK expression absent (Protein)	25	Bacterial infection (IBD, CLD)	None	+	Chronic Haemophilus influenzae infection of eye, Persistent COVID-19, Giardia in GI tract	Left lobectomy	PBSC	12/12	NA	Treo 42 g/m2, Fludarabine 150 mg/m2, TT 10 mg/kg, ALZ 1 mg/kg	RT-MAC	CsA, MMF	5.6	3.2	-
17	5	c.43 C > T, p.Gln15Ter	22	Norovirus infection	None	None	Chronic norovirus infection, Severe GI and GU fistula, Recurrent UTI	None	PBSC	10/10	Unrelated donor	Treo 42 g/m2, Fludarabine 150 mg/m2, TT 10 mg/kg, ALZ 1 mg/kg	RT-MAC	CsA, MMF	6.6	6.5	-
18	0.8	NA	3	Bacterial infection	None	None	Pneumonia, Gastroenteritis	None	PBSC	5/10	Haploidentical paternal donor	TT, Treo, Flu, rATG (Data of dose is NA)	RT-MAC	TCRαβ depletion	-	15	-
19	1	c.1816 C > T, p.Arg562Trp	18	Aichi virus infection	None	None	Disseminated Aichi infection (Severe renal damage)	None	PBSC	NA	Haploidentical maternal donor	Treo 42 g/m2, Flu 160 mg/m2, TT 10 mg/kg, ATG (G) 45 mg/kg	RT-MAC	TCRαβ depletion	5	45	[19]
20	6	c.1750 + 5G > A	42	CD8 T-cell LPD	None	None	None	+	PBSC	10/10	NA	Me 140 mg/m2, Flu 120 mg/m2, TT 10 mg/kg, ATG (G) 30 mg/kg	RT-MAC	CsA, MMF	5.8	5.0	-
21	4	NA	6	Bacterial infection	None	None	Pneumonia, GI infection	None	PBSC	5/10	NA	Treo, Flu, ATG (T) (Data of dose is NA)	RIC	PTCY, Siro, MMF	NA	11	-
22	13	c.-31 + 1G > A	13	Aichi virus infection	None	None	Nodular regenerative hyperplasia and chronic hepatitis	None	PBSC	NA	Haploidentical paternal donor	TT, Treo, Flu (Data of dose is NA), ALZ 1 mg/kg	RT-MAC	TCRαβ depletion	7.5	9.7	-
22-re			13						PBSC	NA	Haploidentical maternal donor	Flu, ATG (Data of dose is NA)	RIC	NA	NA	NA	-

IBD Inflammatory bowel disease, LPD Lymphoproliferative disease, HCT Hematopoietic cell transplantation, CLD Chronic lung disease, GVHD Graft-versus-host disease, NCC Nucleated cell count, AML Acute myeloid leukemia, ALL Acute lymphoblastic leukemia, MRD Minimal residual disease, SCD Sickle cell disease, BM: Bone marrow, PBSC: Peripheral blood stem cell, UCB Umbilical cord blood, BU Busulfan, CY Cyclophosphamide, McAb Monoclonal antibody, TBI Total body irradiation, ETP Etoposide, ATG Anti-thymocyte globulin (T Thymoglobuline, G Grafalon), Flu Fludarabine, Treo Treosulfan, TT Thiotepa, Ara-C Cytarabine, RTX Rituximab, MAC Myeloablative conditioning, RTC Reduced toxicity conditioning, CsA Cyclosporin, sMTX Short-term methotrexate, MMF Mycophenolate mofetil, PTCY Post-transplant cyclophosphamide, Siro Sirolimus, GI Gastrointestinal, GU Genitourinary, UTI Urinary tract infection, NA Not available, *No detailed informationa

The corrected table is on the next page.

The original version has been corrected.